About Index Trending news
Analyze
Pricing
BIND Therapeutics

BIND Therapeutics

Work at BIND Therapeutics? Add yourself to this profile

BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
Edit Profile
More info

Elsewhere

Also headquartered in Cambridge

MIT MIT Raspberry Pi Raspberry Pi ARM ARM Xconomy Xconomy Mobile.co Mobile.co HubSpot HubSpot nuTonomy nuTonomy Biogen Biogen Sarepta Therapeutics Sarepta Therapeutics General Catalyst General Catalyst

Companies in the same industry

Merck Merck Holganix Holganix Clovis Oncology Clovis Oncology Zephyrus Biosciences Zephyrus Biosciences Sanovas Sanovas FITBIONIC FITBIONIC Esperion Therapeutics Esperion Therapeutics MetaStat Inc. MetaStat Inc. Restored Hearing Restored Hearing RxAdvance RxAdvance

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 2
Add info
Latest funding
Venture capital (Series D)
$25,500,000
RUSNANO
Venture capital (Series C)
$12,400,000
Endeavour Vision, Flagship Ventures, Polaris Partners, +2
Employees

Team size

50+
Locations
HQ
Cambridge, United States
Headquarters
Xconomy

Pfizer Might Buy Bind Therapeutics From Bankruptcy for $20M

Health Legal
Pfizer Inc.
Pfizer Inc.
BIND Therapeutics
BIND Therapeutics
Xconomy

Bind Therapeutics Sheds Employees, Considers New Capital or Deals

Health Funding
BIND Therapeutics
BIND Therapeutics